These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 17699871)

  • 1. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.
    Ritter CA; Perez-Torres M; Rinehart C; Guix M; Dugger T; Engelman JA; Arteaga CL
    Clin Cancer Res; 2007 Aug; 13(16):4909-19. PubMed ID: 17699871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
    Chan CT; Metz MZ; Kane SE
    Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
    Rexer BN; Ghosh R; Narasanna A; Estrada MV; Chakrabarty A; Song Y; Engelman JA; Arteaga CL
    Clin Cancer Res; 2013 Oct; 19(19):5390-401. PubMed ID: 23948973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
    Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
    Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.
    Ghosh R; Narasanna A; Wang SE; Liu S; Chakrabarty A; Balko JM; González-Angulo AM; Mills GB; Penuel E; Winslow J; Sperinde J; Dua R; Pidaparthi S; Mukherjee A; Leitzel K; Kostler WJ; Lipton A; Bates M; Arteaga CL
    Cancer Res; 2011 Mar; 71(5):1871-82. PubMed ID: 21324925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
    Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
    Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.
    Xu H; Yu Y; Marciniak D; Rishi AK; Sarkar FH; Kucuk O; Majumdar AP
    Mol Cancer Ther; 2005 Mar; 4(3):435-42. PubMed ID: 15767552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.
    Nahta R; Yuan LX; Du Y; Esteva FJ
    Mol Cancer Ther; 2007 Feb; 6(2):667-74. PubMed ID: 17308062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
    Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
    Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
    Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
    Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
    Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
    Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.
    Garrett JT; Sutton CR; Kuba MG; Cook RS; Arteaga CL
    Clin Cancer Res; 2013 Feb; 19(3):610-9. PubMed ID: 23224399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
    Yao E; Zhou W; Lee-Hoeflich ST; Truong T; Haverty PM; Eastham-Anderson J; Lewin-Koh N; Gunter B; Belvin M; Murray LJ; Friedman LS; Sliwkowski MX; Hoeflich KP
    Clin Cancer Res; 2009 Jun; 15(12):4147-56. PubMed ID: 19509167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.
    Knowlden JM; Hutcheson IR; Jones HE; Madden T; Gee JM; Harper ME; Barrow D; Wakeling AE; Nicholson RI
    Endocrinology; 2003 Mar; 144(3):1032-44. PubMed ID: 12586780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing.
    Kute TE; Savage L; Stehle JR; Kim-Shapiro JW; Blanks MJ; Wood J; Vaughn JP
    Cancer Immunol Immunother; 2009 Nov; 58(11):1887-96. PubMed ID: 19340424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
    Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
    Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.
    Sassen A; Diermeier-Daucher S; Sieben M; Ortmann O; Hofstaedter F; Schwarz S; Brockhoff G
    Breast Cancer Res; 2009; 11(4):R50. PubMed ID: 19624808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.